UTAH MEDICAL PRODUCTS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
UTAH MEDICAL PRODUCTS, INC. (UTMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.76% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-27
- UTAH MEDICAL PRODUCTS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.76%, a 11.11% decline from fiscal 2024.
- UTAH MEDICAL PRODUCTS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.23%, a 10.95% decline from fiscal 2023.
- UTAH MEDICAL PRODUCTS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.75%, a 16.14% increase from fiscal 2022.
- UTAH MEDICAL PRODUCTS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 4.09%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|
| 2025-12-31 | 3.76% 10-K · filed 2026-03-27 |
| 2024-12-31 | 4.23% 10-K · filed 2026-03-27 |
| 2023-12-31 | 4.75% 10-K · filed 2026-03-27 |
| 2022-12-31 | 4.09% 10-K · filed 2025-03-26 |
| 2020-12-31 | 0.56% 10-K/A · filed 2023-03-28 |
| 2019-12-31 | 0.00% 10-K · filed 2020-03-16 |
| 2018-12-31 | 2.57% 10-K · filed 2021-03-26 |
| 2017-12-31 | 0.00% 10-K · filed 2020-03-16 |
| 2016-12-31 | 1.30% 10-K · filed 2019-03-14 |
| 2014-12-31 | 1.50% 10-K · filed 2017-03-08 |
| 2012-12-31 | 0.54% 10-K · filed 2015-03-12 |
| 2011-12-31 | 1.19% 10-K · filed 2014-03-12 |
| 2010-12-31 | 2.08% 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |